MidAmerica Healthcare Venture Forum: Speakers

Speakers

Rod Altman: Senior Partner
CMEA Ventures; Rodney D. Altman, MD joined CMEA Capital in 2006. Prior to joining CMEA, he was a founder and managing director of Aphelion Capital. Previously, he also worked at Piper Jaffray Ventures and was a partner at TVM Techno Venture Management. Before joining TVM, Rod practiced emergency medicine for 10 years. He was the Assistant Medical Director of the emergency department at MacNeal Hospital in suburban Chicago and a Clinical Instructor at the University of Chicago. On a limited basis, Rod continues to practice emergency medicine at Stanford University Medical Center where he is a Clinical Assistant Professor of Emergency Medicine in the Department of Surgery. He graduated from McGill University's Faculty of Medicine as a University Scholar and from University of Chicago's business school with honors. Rod is a Fellow of the American College of Emergency Physicians. At CMEA, he focuses on investments in medical devices, biotechnology therapeutics, and diagnostics. Rod serves as a director on the boards of SurgiQuest, InSound Medical, VasoNova, and Visiogen.

Kevin Conroy: President & CEO
Exact Sciences Corp; Kevin T. Conroy was named president and chief executive officer of Exact Sciences in April 2009. He also serves as a director of the company. In December 2005, he was appointed president and chief executive officer of Third Wave Technologies Inc. and served in that position until the company's acquisition by Hologic Inc. in July 2008. He joined Third Wave in July 2004 and served as the company's general counsel until December 2005. Prior to joining Third Wave, Mr. Conroy served as intellectual property counsel at GE Healthcare. Before joining GE Healthcare, Mr. Conroy was chief operating officer of two early-stage, venture-backed technology companies in northern California. Prior to those positions, he was an intellectual property litigator at two Chicago law firms, McDermott Will & Emery, and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a partner. He earned a bachelor's of science degree in electrical engineering at Michigan State University and a law degree the University of Michigan Law School.

Mark DuVal: President
DuVal & Associates; Mark E. DuVal, JD is President of DuVal & Associates, where he counsels both mature and venture-backed pharmaceutical, medical device, and biotech companies in the United States and Europe in addition to working extensively with combination products. DuVal regularly advises clients in all areas of FDA law and regulation, from product development, clinical trials, inspections and recalls to reimbursement and compliance issues and post-marketing responsibilities. He specializes in counseling medical device and pharmaceutical companies in the development and implementation of strategic and tactical sales and marketing plans that are appropriately aggressive, yet compliant.

George Emont: Managing Partner
Triathlon Medical Ventures; George Emont is a Managing Partner with Triathlon Medical Ventures and a Managing Partner of the Kentucky Seed Capital Fund. Mr. Emont’s more than two decades of health care industry experience include 14 years in venture capital. Prior to joining Triathlon and KCSF, Mr. Emont was Director of Venture Capital for Humana Inc. where he managed a venture capital fund that made investments totaling over $75 million in 11 portfolio companies and three venture funds. Mr. Emont’s resume includes service with Baxter Healthcare Corporation and IAI Venture Capital Group, followed by the successful launch and eventual sale of oncology-focused biotechnology start-up OncoTherapeutics. Mr. Emont currently is on the boards of Celleration, Juventas Therapeutics, Pradama, ApoImmune, RhinoCyte, AllTranz and OrthoData. Mr. Emont is from Granville, Ohio, holds a B.A. from Oberlin College in Oberlin, Ohio, and an M.B.A. from the University of Chicago.

R. John Fletcher: Chief Executive Officer
Fletcher Spaght Ventures; John Fletcher founded Fletcher Spaght, a 26 year old strategy consulting firm focused on new ventures in technology and life sciences. John is also a Managing Partner of Fletcher Spaght Ventures, a venture capital fund. Mr. Fletcher divides his time between active sourcing of venture capital investments, and developing and conducting strategy studies for venture-backed technology companies. Currently, he is a member of the Boards of Directors of four publicly-held technology companies, Axcelis, AutoImmune, Spectranetics and Xvionics. He also serves on the Boards of Advisors of the Cardiology Council of Children’s Hospital, the Whitehead Institute at MIT, the Thayer School of Engineering at Dartmouth College, and the School of Government and Business at George Washington University. Prior to launching FSI in 1983, Mr. Fletcher was a Senior Manager at The Boston Consulting Group, managing global client relationships with healthcare and high technology companies. Mr. Fletcher was a Ph.D. candidate and instructor in International Business at the Wharton School of the University of Pennsylvania. Prior to Wharton, he was a Captain and jet pilot in the U.S. Air Force. Mr. Fletcher holds an M.A. in Finance from the Wharton School, an M.B.A. from Southern Illinois University and a B.A. from George Washington University.

Ashley Friedman: Senior Associate
Investor Growth Capital, Inc.; Ashley joined Investor Growth Capital’s New York office with the Healthcare team in 2003. He focuses primarily on medical device and biopharmaceutical investments. Prior to joining Investor Growth Capital, Ashley worked in the healthcare investment banking group at Lehman Brothers. Ashley received his Bachelor of Science degree from Yale University in both Molecular Biology and Economics. Ashley currently serves as a Director on the Board of Axiomed Spine Corporation and is a Board observer at Applied Spine Technologies, Biolex Therapeutics, Cayenne Medical and CHF Solutions.

Jan Garfinkle: Managing Director
Arboretum Ventures; Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering to select and nurture outstanding companies. Jan currently serves on the board of directors for HandyLab and NXThera Inc., and as an observer for Aptus Endosystems, BAROnova, Esperion Therapeutics and Uptake Medical. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions and was Founder and President of Strategic Marketing Consultants. Earlier in her career, Jan was part of the senior management team for two successful medical device start-up companies, advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired and became part of Guidant Corporation. Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Michael E. Jenkins, PhD: General Manager
Catalent Pharma Solutions; Michael earned a B.S. in Microbiology from the University of Illinois and a PhD in Molecular and Cellular Biology from the University of Arizona. He was the ninth employee at CropTech Development Corporation in Blacksburg Virginia where he served in a technical role having the dream job of using tobacco to attempt to cure cancer, before transitioning to a Business Development role. After leaving CropTech, he joined Goodwin Biotechnology Inc., a mammalian cell culture CMO where he was responsible for Worldwide Business Development activities. After Goodwin he joined Gala Biotech in 2003 serving as Director of Business Development and Commercial Operations with Gala until he was promoted to Vice President, Business Development in 2006 and then General Manager of the Middleton facility in 2008. He has been associated with the facility as part of Gala Biotech, Cardinal Health and Catalent Pharma Solutions.

Michael’s primary areas of interest include traditional and transgenic biologics manufacturing platforms as well as the evaluation and establishment of novel technologies in the biotechnology marketplace and Michael can occasionally be found sailing on lake Mendota and watching his kids play soccer in the Madison area.

Dr. Sangtae "Sang" Kim: Executive Director
Morgridge Institute for Research; Dr. Kim brings a unique combination of academic, industry and government agency experience to bear on the problem of drug discovery and development. He came to the Morgridge Institute in 2008 from Purdue University, where he was the Donald W. Feddersen Distinguished Professor of Mechanical Engineering and Distinguished Professor of Chemical Engineering. During his six years in industry, Dr. Kim led research and development efforts at the pharmaceutical giants Eli Lilly and Pfizer. He also served the National Science Foundation as director of the division of shared cyber-infrastructure in 2004-2005, while on loan from Purdue University. In 2001, Dr. Kim was named a member of the National Academy of Engineering for his contributions to micro-hydrodynamics, protein dynamics, and drug discovery through the application of high-performance computing. After earning a master’s degree from the California Institute of Technology, Dr. Kim received a doctorate in chemical and biological engineering from Princeton University in 1983. He joined the UW-Madison faculty in 1983 and served as chair of the Department of Chemical Engineering from 1995-1997. During that time, he also was granted a rare “courtesy appointment” in the Department of Computer Sciences.

Christopher J. King: Senior Director, Corporate Development
Medtronic, Inc.; Chris King is Senior Director, Corporate Development for Medtronic, Inc. Chris has responsibility for the Cardiac Rhythm Disease Management, Neuromodulation and Diabetes businesses where he works in partnership with executive and business unit management in evaluating and executing corporate development opportunities, including mergers and acquisitions, strategic alliances, joint ventures, minority investments, technology licenses, and divestitures. Prior to joining the Corporate Development team, Chris was Director of Investor Relations and Corporate Strategy responsible for cultivating and maintaining Medtronic’s relationship with the broad-based investment community in addition to supporting Medtronic’s strategic planning process. Chris began his career with Medtronic in 1996 with his first assignment in Corporate Finance. Chris has served as Director, e-Business with responsibility for our Global Healthcare Exchange Partnership and his Medtronic career also includes positions in Cardiac Surgery and a previous role in Corporate Development. Prior to joining Medtronic, Chris spent five years in various engineering positions at Amoco Oil Company. Chris received his undergraduate degree in Mechanical Engineering from The Ohio State University and his MBA in Finance and Business Policy from the University of Chicago.

Peter G Kleinhenz: Venture Partner - Fletcher Spaght Ventures
Managing Director
CID Capital, Inc.; Peter Kleinhenz is a Venture Partner at FletcherSpaght Ventures. He has been actively involved in life science-based businesses for over 25 years as an entrepreneur, consultant, and investor. Currently he serves on the boards of five CID life science portfolio companies. Peter invests in a broad array of life since opportunities with a special interest in medical devices. He joined Fletcher Spaght Ventures in 2009. Prior to joining CID in 2001, Peter served as VP of Commercialization for Battelle Memorial Institute and as an independent consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups. Peter was CEO of Progenics. Inc., a medical device design and manufacturing company and held a variety of senior executive positions at Neoprobe Corporation, a biotech and medical device company focused on cancer diagnostics and therapeutics, including CFO and Vice President of Product and Market Planning. Peter received an MBA from Case Western Reserve University, a Bachelor's degree from Loyola University of Chicago, and is a Certified Public Accountant, Ohio.

Mark Koch: Chief Administrative Officer
Mayo Health System; Mr. Mark B. Koch currently serves as the Chief Administrative Officer for the Mayo Health System. He received his Bachelor of Arts degree from St. John's University and MBA from Winona State University. Mr. Koch has served in a number of progressive assignments at Mayo Clinic including Human Resource Generalist in the Department of Human Resources, Operations Manager in the Department of Finance, Administrator for the Division of Cardiovascular Diseases, Administrator for the Department of Internal Medicine, Administrator for the Department of Obstetrics and Gynecology and Administrative Chair/Associate Administrator for Surgery and Surgical Specialties. Mr. Koch is a member of the Medical Group Managers Association and holds certification in the American College of Medical Practice Executives. He has served on a number of non-profit boards of directors in the Rochester community including the American Heart Association and Catholic Charities, Diocese of Winona. He has also been active as a coach in youth sports.

Paul Kusserow: Senior Vice President and Chief Strategy Officer
Humana, Inc.; Paul Kusserow joined Humana as Senior Vice President and Chief Strategy Officer in February 2009 with responsibility for Humana’s strategic planning function as well as its merger and acquisition and venture-capital activities. He is one of six direct reports to the President and Chief Executive Officer and a member of the Corporate Executive Committee which sets strategic direction for the company.

Prior to joining Humana, Mr. Kusserow served as Managing Director of Private Equity at the Chicago-based investment firm B.C. Ziegler and Company. He also served as Managing Director and Chief Investment Officer of the Ziegler HealthVest Fund, where he focused on early-stage investments in health care services and health care IT. From 2004 to 2007, he was Managing Director of San Ysidro Capital Partners LLC, a health care services consulting and investment advisory firm. From 1999 to 2004, he served as Senior Vice President, Corporate Strategy and Tenet Ventures, at Tenet Healthcare Corporation, where he was responsible for identifying, evaluating and directing the company’s investments as well as implementing corporate strategy initiatives. Prior to joining Tenet, Mr. Kusserow was President of Roaring Mountain, a private investment and consulting firm. Before that, he was head of planning and marketing at the Colonial Williamsburg Foundation, where he was responsible for strategic planning, new business development and marketing. He started his career at the management consulting firm of McKinsey and Company, where he specialized in marketing and organizational redesign.

A Vermont native, Paul is a Phi Beta Kappa graduate of Wesleyan University, where he was a Brown Scholar, Olin Fellow and Fellow at the Center for the Humanities. He received his Master of Arts degree in English Literature from the University of Oxford, where he was a Rhodes Scholar.

David G. Lowe, PhD: Managing Director
Skyline Ventures; Prior to joining Skyline in 2002 David was at Genentech for 16 years as a scientist and Director of Cardiovascular Research. At Genentech, David led drug discovery activities in biologics and small molecule therapeutics. He was a member of the therapeutic area team responsible for cardiovascular strategic planning and product portfolio management, and worked on in-licensing of early and late-stage therapeutics, and technology access. Currently he serves on the board of directors for the privately held companies InteKrin Therapeutics, Proteon Therapeutics, and Sequel Pharmaceuticals, and previously served on the board of directors of Avidia (acquired by Amgen), NimbleGen Systems (acquired by Roche), and NovaCardia (acquired by Merck). David holds a Ph.D. in biochemistry from the University of Toronto, Canada.

Dan Mans: Vice President
Research and Technology
American Medical Systems; Dan Mans is a seasoned medical device executive with experience leading clinical, regulatory, research, and engineering functions. He has brought complex medical devices from concept through market launch, having twice led successful FDA Panel defenses of novel technologies. Mr. Mans has led clinical studies on 3 continents. His work spans the range from early stage start-up companies to large, multi-billion dollar multi-national corporations. He has been a member of four company’s senior management teams, realizing aggressive revenue growth based largely on successful new product development. Dan has a passion for innovation and keen insights into the complex pathways associated with brining new ideas to a profitable position within the market. He earned his Bachelor’s of Science in Mechanical Engineering from the University of Minnesota, where he also pursued a graduate education in human physiology and anatomy.

Rick Mattoon: Senior Economist & Economic Advisor
Federal Reserve Bank; Rick Mattoon is a senior economist and economic advisor in the economic research department of the Federal Reserve Bank of Chicago. Mattoon's primary research focuses on issues that face the Midwest regional economy. His analysis of electricity restructuring and energy issues, higher education policy, regional economic development and state and local government finance has appeared in numerous publications. Mattoon also serves as a lecturer at the Kellogg School of Management at Northwestern University. Mattoon began his career at the Chicago Fed in 1990. In 1997 he left the bank to serve as a policy advisor for economic development, energy and telecommunications to the Governor of Washington. He later served as director of policy and legislation for the Washington Utilities and Transportation Commission. He returned to the bank in 2001. Mattoon received a B.A. from Kenyon College and an M.A. from the University of Chicago.

Carla Monacelli: Managing Partner
Argenta Advisors; Carla has worked in the field of reimbursement, healthcare policy, and government relations for over 19 years. In 2001, she co-founded Argenta Reimbursement Advisors (formerly Certus Healthcare), and in 2007 co-founded Argenta TEC Advisors. In 2007 she co-founded mgine6, a subscription based reimbursement database for government payers

Prior to establishing Argenta, her career experience included lobbying for a top Minnesota law firm and payer relations and reimbursement strategy for multiple clients at a large Washington DC healthcare consulting firm, as well as at the Minnesota Council of Health Plans.

Carla has developed and implemented strategic reimbursement plans for both biotechnology and medical device companies. She has been involved with the launch or reimbursement strategies for over 60 technologies, including three Orphan Drugs. Carla has served as Senior Director of Healthcare Affairs for Conceptus, Inc., since 2004 where she has led the strategic reimbursement planning and tactical implementation of the plan. Carla has recruited, trained, and managed field reimbursement specialists. Her experience has also included management and sales force reimbursement training; health plan education and advocacy, including Medicare, Medicaid, private health plans, worker’s compensation, and self-insured corporations; development of reimbursement tools; and lobbying and grassroots advocacy program development.

Carla holds a bachelor’s degree in political science from the University of Minnesota. She is an adjunct faculty member at St. Cloud State where she is a co-lead instructor for the Master of Regulatory Affairs Health Policy and the Medical Technology Industry and lecturer on developing and implementing a comprehensive strategy for the Reimbursement classes. She is also a past co-chair of Life Science Alley’s Reimbursement Special Interest Group.

Joe Morgan, CFA: Chief Investment Officer and Head of Portfolio Management
SVB Asset Management; Joe Morgan is the chief investment officer and head of portfolio management for SVB Asset Management. For more than 15 years of he has successfully managed fixed income portfolios for the purpose of total return, current income, and liability diffusion. In his current role, Morgan leads a team of portfolio managers and traders that sets and executes investment strategy for all of SVB Asset Management’s client investments. Frequently invited to speak at financial industry events, Morgan is widely sought out by business media and influencers for his perspective on issues affecting the fixed income market. He is most well recognized for his leadership in exiting and speaking out about the substantial risks associated with auction rate securities since 2004. The Wall Street Journal called Morgan “The Auction Rate Cassandra” once the market started to fail in 2008. Morgan authors a weekly economic outlook column, among several other publications. Prior to joining SVB, Morgan was a senior portfolio manager with City National Asset Management in Beverly Hills, and was responsible for the bank's taxable fixed income total return oriented clients. He also spent seven years with Seneca Capital Management in San Francisco. At Seneca, he was responsible for managing institutional fixed income assets totaling over $5 billion with various return objectives and benchmarks. Morgan received both his bachelor's and master's degrees in finance from Texas A&M University, and is a Chartered Financial Analyst.

John Neis: Managing Partner
Venture Investors; John Neis is a Managing Director and heads the firm's Healthcare practice. He has over 23 years in the venture capital industry, which have enabled him to experience several industry cycles, and to serve on the board of directors of companies from formation through IPO or sale. John currently serves on the boards of directors of Virent Energy Systems, Deltanoid Pharmaceuticals and Cellectar. He is a former member of the boards of directors of several firms including Tomo Therapy, Third Wave Technologies and NimbleGen Systems. John was appointed by the Governor to the Board of the Wisconsin Technology Council. He also serves on the advisory boards for the Weinert Applied Ventures Program, The University of Wisconsin-Madison Business School and Tandem Press. He is a member of the patent advisory group of the NVCA. His achievements were recognized when he was named to the 2008 Midas List, Forbes annual listing of the top 100 tech dealmakers in the world. John graduated Magna Cum Laude with a B.S. in Finance from the University of Utah, and received a M.S. in Marketing and Finance from the University of Wisconsin-Madison. He is a Chartered Financial Analyst.

Charles O’Meara Senior Managing Director -: Private Equity
B.C. Ziegler & Company; Charles O’Meara is Senior Managing Director - Private Equity of Ziegler, a 100 year old financial services company with a focus on providing financing solutions to healthcare providers. Mr. O’Meara was instrumental in founding Ziegler’s venture capital practice in 2006, which currently consists of two funds investing in companies developing new technology in medical devices and healthcare provider support services and IT. Ziegler also sponsors private equity offerings in healthcare real estate, and provides M&A advisory services to companies developing healthcare technology. Chuck received an AB from the University of Notre Dame, and a JD from Marquette University Law School.

Peter Sausen: Global Vice President, Integrated Drug Development
Covance Laboratories; Dr. Sausen received his doctorate in Toxicology from the University of Wisconsin-Madison in 1992. Following completion of a postdoctoral fellowship at the Chemical Industry Institute of Toxicology, Dr. Sausen was responsible for supporting preclinical development of cyclooxygenase-2 inhibitors at G.D. Searle and Company. He joined Eli Lilly and Company in 1997 and was a Head in the Nonclinical Safety Assessment group that was responsible for preclinical development programs in the areas of neuroscience, endocrine, inflammation, erectile dysfunction, and cardiovascular disease. In addition, Dr. Sausen was responsible for the conduct of nonclinical safety studies, and was the primary author of regulatory submission documents and responses to regulatory questions for the worldwide submission of Cialis®. Dr. Sausen was one of the pivotal members of the Cialis® team that defended the safety profile of Cialis® to the FDA, CPMP, China CDE, Canada HBP and the MHLW in Japan. Dr. Sausen is currently the Vice President of Global Program Management Services at Covance Laboratories. In this role, he leads a group of senior scientists and professional project managers in North America and Europe who help drug companies of all sizes with their drug development needs from preclinical safety assessment through clinical proof of concept studies. Dr. Sausen was recently the co-author on several articles that emphasize the effective utilization of program and project management to facilitate drug development.

Brian Scullion: Partner
William Blair & Company; Brian F. Scullion, M.D., Partner, joined the Corporate Finance department in 1999. Dr. Scullion has executed transactions in numerous healthcare sectors including for medical device, pharmaceutical and healthcare services businesses. Previously, Dr. Scullion was the Chief Medical Officer at Vida Healthcare, a cancer disease management concern. Prior to joining Vida, Dr. Scullion was a medical director at several health plans and practiced internal medicine at Rush University Medical Center in Chicago. Dr. Scullion, who is a licensed physician, received an AB (magna cum laude) from Columbia University, an MD from Stanford University and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

Robert A. Shalwitz: Vice President & CMO
Akebia Therapeutics, Inc.; Dr. Shalwitz co-founded Akebia in 2007. Prior to Akebia, Dr. Shalwitz was Vice President of Clinical Development at Reliant Pharmaceuticals, where he led a clinical team which launched and completed numerous clinical trials for the treatment of lipid and cardiac disorders, and contributed to several FDA filings. Before Reliant, Dr. Shalwitz was Medical Director at Abbott Labs. During his 10-year tenure at Abbott Labs, Dr. Shalwitz’s team gained FDA approval for two NDAs (in lipid and cardiac disease). In addition, he acquired experience in all phases of drug development, from preclinical to Phase IV. Complementing his work in clinical development, Dr. Shalwitz has also become very experienced in pharmaco-vigilance and post-marketing medical affairs. Prior to Abbott Labs, Dr. Shalwitz was an academic pediatric endocrinologist for 10 years. His research at Washington University in St. Louis and at the Children’s Hospital of Orange County (CA) focused on glucose and glycogen metabolism. Dr. Shalwitz received an M.D. degree from SUNY Buffalo and a BGS degree from the University of Michigan.

Kelly Slone: Director, Medical Industry Group
National Venture Capital Association (NVCA); Kelly Slone joined the National Venture Capital Association (NVCA) in April 2005. NVCA represents over 400 venture capital firms. Its mission is to foster the understanding of the importance of venture capital to the vitality of the U.S. and global economies. Kelly is the Director of the Medical Industry Group (MIG) for NVCA. She is responsible for raising the visibility of the life science investors in the development of medical therapies and technologies. She is also is the lead lobbyist on policy issues that primarily impact life science investors. Kelly spent eleven years at Baxter Health Corporation as a director of government affairs and lobbied on health care, tax and product liability issues on behalf of the company. Prior to joining Baxter, he held other health care policy related positions including a two year political appointment at the Department of Health and Human Services Office of the Assistant of Legislation and two years staffing Senator Orrin Hatch who was the Chairman of the Senate Labor and Human Resources Committee.

Mina Patel Sooch: Managing Partner
Apjohn Ventures / Triathlon Medical Ventures; Mina Sooch brings with her over fifteen years of pharmaceutical and healthcare experiences as an entrepreneur, strategy & finance advisor, and venture capitalist. Since 2000, she has helped co-found Apjohn Ventures, Apjohn Group, and several local start-ups and is current managing partner at Apjohn Ventures (2003 LS Fund) and Triathlon Medical Ventures II. Mina has served on 9 portfolio company boards as a VC and serves on the boards of the Midwest Healthcare Investment Network and Michigan Venture Capital Association (currently Chariman). Prior to 2000, Mina spent eight years as a global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with her client base consisting of mid-cap and large-cap healthcare companies and multi-billion dollar private equity companies. With a focus on M&A, she has worked on over 30 deals including $7B Pharmacia & Upjohn merger in 1995. Mina was also a co-founder of Monitor's Corporate Finance practice in 1998. Mina received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.

Tom Still: President
Wisconsin Technology Council; Tom Still is president of the Wisconsin Technology Council and the Wisconsin Innovation Network. He is the former associate editor of the Wisconsin State Journal in Madison. Still serves on the board of directors for the Wisconsin Security Research Consortium and “We the People/Wisconsin,’ the UW-Extension Board of Visitors, the UW-Madison College of Engineering Industrial Advisory Board, and the WiSys Technology Foundation Advisory Board, among other civic and business groups. He moderated the Wisconsin Economic Summits (2000-2003) and writes a syndicated column that appears regularly in 24 publications. He is a lecturer in the UW-Madison College of Agricultural and Life Sciences. Still is the co-author of “Hands-On Environmentalism,” published by Encounter Books, New York.

John S. Taylor: Vice President of Research
National Venture Capital Association; John S. Taylor is Vice President of Research at National Venture Capital Association (NVCA) which is based in the Washington, DC area. He joined in 1996 and is responsible for developing and overseeing association data and research efforts. The key element in this effort is the creation of a research consortium which was announced in 1998 involving the NVCA and Venture Economics, now Thomson Reuters. With strong member support and encouragement from the Ewing Marion Kauffman Foundation, it quickly became the industry’s leading data source. In December 2001, PricewaterhouseCoopers joined the team and the tri-branded MoneyTreeÔ Report report which became the definitive source for venture capital investment information. Building on this information, the NVCA has been able to develop and encourage research and studies which provide greater transparency into the process of creating tomorrow’s great companies.

Mr. Taylor is frequently quoted by major newspapers and magazines on the subject of venture capital and has recently provided live commentary on CNBC, CNNfn, Bloomberg radio, and NPR Morning Edition.

Mr. Taylor’s career began with the company now known as Accenture where he was a senior consultant advising small business clients. He has since held senior product manager and IT positions in both large and small organizations. At a national computer services provider, he helped develop a new generation of minicomputer and microcomputer products for the residential real estate MLS industry. He joined the NVCA in 1996.

He has served as a board member of both for-profit businesses and non-profit organizations. In 1998, he was awarded the Maryland Governors Citation for outstanding volunteer service. He recently joined the Advisory Board of the Center for Private Equity and Entrepreneurship at the Amos Tuck School.

When he’s not chasing down IPOs and deals, he has been spotted chasing down errant golf shots in the woods, heading down the ski slopes, and pouring at wine festivals to help local Virginia wineries (none of which, alas, is venture-backed).

He is also a noted amateur photographer with several web and publication photo credits including the May/June 2009 Symphony Magazine cover.

He received an MBA degree from the Amos Tuck School at Dartmouth College, and a BS degree in chemistry from Dickinson College.

Tracy Warren: General Partner
Battelle Ventures; Tracy Warren is a general partner of Battelle Ventures, a $220-million fund based in Princeton, N.J., and of its Knoxville, Tenn.-based, $35-million affiliate fund, Innovation Valley Partners, for which she focuses on investments in health & life sciences and emerging energy technologies. Among her health & life sciences venture activities, Ms Warren is acting CEO of regenerative-medicine company NellOne Therapeutics, a board director of both DNA-sequence-analysis company BioNanomatrix and cardiovascular-device company Endovalve, and a board observer of CNS-specialty-pharmaceutical company NuPathe. She also is a member of the Ben Franklin Technology Partners biotechnology and life sciences investment advisory committee and was on the program committee for the May 2009 American Society for Artificial Internal Organs 55th Annual Conference. Ms Warren started in venture capital in 2001 after being an analyst and associate in SG Cowen (now Cowen and Company) Securities & Health Care Mergers and Acquisitions and Corporate Finance divisions.

Dr. John D. Wiley: Director – Wisconsin Insititutes for Dicovery
Former Chancellor – UW-Madison; Dr. John D. Wiley is director of the Wisconsin Institutes for Discovery, and the former chancellor of UW-Madison. Prior to his appointment as chancellor, Wiley had served as the university's provost and vice chancellor for academic affairs. Wiley has represented the institution for a variety of external constituencies, including alumni groups, the boards of trustees of university-affiliated foundations and other organizations, domestic and international inter-university cooperatives, chambers of commerce and service clubs, the state Legislature and governmental bodies, the UW System Administration, and the UW System Board of Regents. Wiley received his bachelor's degree in physics from Indiana University in 1964; attended graduate school at UW-Madison as an NSF Fellow; and received master's and doctoral degrees in physics in 1965 and 1968, respectively.